Chimeric antigen receptor and application thereof

A technology of chimeric antigen receptors and antigens, applied in medicine, in the field of chimeric antigen receptors, can solve problems such as low expression levels
CN111499723AActive Publication Date: 2020-08-07GUANGZHOU BIO GENE TECH CO LTD
6 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
GUANGZHOU BIO GENE TECH CO LTD
Publication Date
2020-08-07

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention provides a chimeric antigen receptor and application thereof. According to the chimeric antigen receptor, modified BAFF is adopted as an antigen binding structural domain, the modified BAFF retains the BAFF-R bonding capability, however, malignant B cell proliferation caused by BAFF activation cannot be caused, the constructed CAR molecule can recognize and combine BAFF-R, so that the prepared CAR-T cell has a specific targeted killing effect on BAFF-R positive and CD19 negative B tumor cells, and is expected to become a new means for treating tumor recurrence caused by CD19 antigen deletion.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the field of biological technology and the technical field of cellular immunotherapy of diseases, and relates to a chimeric antigen receptor and its application, in particular to a chimeric antigen receptor targeting BAFF-R positive tumor cells and its preparation Application of drugs for treating tumor recurrence caused by CD19 antigen deficiency. Background technique

[0002] Chimeric antigen receptor (CAR) T cells have been widely used in the treatment of B-cell malignancies, and CAR-T cells targeting CD19 are the pioneers of CAR-T therapy for B-cell malignancies, providing an effective treatment for B-cell malignancies. Program. However, tumor recurrence caused by the loss of CD19 antigen greatly weakens the therapeutic effect. CD19-negative relapse has become an important problem and occurs in approximately 30% of patients. Related targets of B cells also include CD20 and CD22, etc., but their expression levels in B cel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More